相关实验视频

Updated: May 2, 2026

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

A Hydrogel Construct and Fibrin-based Glue Approach to Deliver Therapeutics in a Murine Myocardial Infarction Model.

Published on: June 14, 2015

来自可降解聚胺的易发炎的小粒子纳米颗粒,用于向心肌梗塞

Yifei Liang¹, Holly L Sullivan², Kendal Carrow^3,4

¹Department of Chemistry, International Institute for Nanotechnology, Simpson-Querrey Institute, Chemistry of Life Processes Institute, Northwestern University, Evanston, Illinois 60208, United States.

Journal of the American Chemical Society

|May 15, 2023

概括

研究人员开发出新的可生物降解纳米颗粒, 这些自我组装的细胞在心肌梗塞后积聚在心脏中, 为向药物输送提供了一个有前途的平台.

科学领域:

聚合物化学
材料科学
生物医学工程

背景情况:

以前开发的针对炎症的纳米粒子缺乏生物降解性.
生物降解材料对于减少与医疗植入物和药物输送系统相关的长期健康风险至关重要.

研究的目的:

开发一种新的可生物降解纳米粒子平台以针对炎症.
制造能够响应炎症特异性酶的纳米颗粒,
在心肌梗塞模型中评估这些纳米颗粒的疗效和生物分布.

主要方法:

一种新型循环烯单体 (MePTDO) 的环开转化聚合.
与功能化的norbornene单体共聚,以产生刷共聚物.
将共聚物自组装成小粒纳米颗粒,并评估矩阵金属蛋白酶 (MMP) 诱导的聚合.
在心肌梗塞 (MI) 的老鼠模型中进行体内注射,以评估生物分布和向.

主要成果:

成功合成了具有高单体转化率 (> 84%) 的明确可降解的多胺酸盐.
开发出能够自组装成30纳米的两性刷共聚物,表现出细胞兼容性和血液兼容性.
已证明MMP诱导的纳米颗粒在心脏病发作后的体内蓄积.
观察到明显的生物分布和清除模式,对可生物降解纳米颗粒而言,脏清除占主导地位.

结论:

开发的基于MePTDO的多胺为向性炎症提供了一个有前途的生物降解平台.
适应MMP的纳米颗粒可能会在发炎部位积聚,例如心肌梗塞后的心脏.
这些可生物降解的纳米颗粒与不可生物降解的对应物相比具有有利的生物分布和清除特征.

更多相关视频

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model

Intramyocardial Transplantation of MSC-Loading Injectable Hydrogels after Myocardial Infarction in a Murine Model

Published on: September 20, 2020

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Ultrasound-Guided Induced Pluripotent Stem Cell-Derived Cardiomyocyte Implantation in Myocardial Infarcted Mice

Published on: March 30, 2022

相关概念视频

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...